nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

17.10.2017 | Original Article

Surgical management of splenic marginal zone lymphoma

verfasst von: N. D. Kennedy, G. N. Lê, M. E. Kelly, T. Harding, K. Fadalla, D. C. Winter

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma with variable prognosis. As a result, there is sparse knowledge on the role of splenectomy and best management approaches. We aim to explore management strategies and outcomes amongst the cohort of SMZL patients at our centre.

Method

A retrospective review of all splenectomies performed at a tertiary referral unit over a 23-year period was assessed. Immunohistochemical and pathological results of splenic samples, bone marrow biopsies, and peripheral blood were compiled. Operative management, surgical, and survival outcomes were assessed. Prognostic stratifications were applied and survival rates were calculated.

Results

Eight cases of SMZL from a database of 693 splenectomies were identified. All patients had intermediate/high-risk disease. All patients underwent splenectomy with one patient receiving preoperative rituximab. All patients had progression-free survival and resolution of disease.

Conclusion

Based on the data obtained, current practice requires defined guidelines and centralised care.

De Pasquale A, Paterlini P, Di Francesco A, Vecchio L, Quaglino D (1986) Follicular lymphomas with predominant splenic involvement: report of two cases. Tumori 72(1):109–115

Swerdlow SH, Campo E, Piler SA et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2. IARC Press, Lyons

Arcaini L, Rossi D, Paulli M (2016) Splenic marginal zone lymphoma: from genetics to management. Blood 127(17):2072–2081CrossRefPubMed

Kalpadakis C, Pangalis GA, Angelopoulou MK et al (2017) Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol 30(1–2):139–148

Matutes E, Oscier D, Montalban C et al (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22(3):487–495

Liu L, Wang H, Chen Y et al (2013) Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma 54(7):1380–1386

Arcaini L, Bruno R (2010) Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol 5(2):74–81CrossRefPubMed

Arcaini L, Paulli M, Boveri E et al (2004) Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 100(1):107–115

Viswanatha DS, Dogan A (2007) Hepatitis C virus and lymphoma. J Clin Pathol 60(12):1378–1383CrossRefPubMedPubMedCentral

10.

Joshi M, Sheikh H, Abbi K et al (2012) Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. Ther Adv Hematol 3(5):275–290

11.

Arcaini L, Rossi D, Lucioni M et al (2015) The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica 100(2):246–252

12.

Du M-Q (2015) Pathogenesis of splenic marginal zone lymphoma. Pathogenesis 2(4):11–20CrossRef

13.

Arcaini L, Lazzarino M, Colombo N et al (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107(12):4643–4649

14.

Olszewski AJ, Castillo JJ (2013) Survival of patients with marginal zone lymphoma. Cancer 119(3):629–638CrossRefPubMed

15.

Montalban C, Abraira V, Arcaini L et al (2011) Stratification approach for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH and extrahilar lymphadenopathy: the HPLL/ABC system. Blood 118(21):1538

16.

Montalban C, Abraira V, Arcaini L et al (2014) Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 55(4):929–931

17.

Kalpadakis C, Pangalis GA, Angelopoulou MK et al (2014) Validation of the simplified prognostic score for splenic marginal zone lymphoma of the splenic marginal zone lymphoma working group. Leuk Lymphoma 55(11):2640–2642

18.

Bennett M, Schechter GP (2010) Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy. Br J Haematol 149:45

19.

Kalpadakis C, Pangalis GA, Vassilakopoulos TP et al (2014) Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma 55(7):1463–1470

20.

Else M, Marín-Niebla A, de la Cruz F et al (2012) Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 159(3):322–328

21.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral

22.

Ponzoni M, Kanellis G, Pouliou E et al (2012) Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol 36(11):1609–1618

23.

Thieblemont C, Nasser V, Felman P et al (2004) Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103(7):2727–2737

24.

Sun Q, Zhang PH, Liu EB et al (2013) Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow. Zhonghua Bing Li Xue Za Zhi 42(4):234–238

25.

Gazzola A, Sabattini E, Mannu C et al (2011) Partial nodal involvement by marginal zone lymphoma. Use of IGK gene rearrangement analysis in diagnostic work-up. Pathologica 103(1):14–18

26.

Munari E, Rinaldi M, Ambrosetti A et al (2012) Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. Virchows Arch 461(6):677–685

27.

Khodzhibekova MM, Tiutin LA, Kostenikov NA et al (2015) 18F–FDG positron emission tomography in the diagnosis and staging of marginal zone non-Hodgkin lymphomas. Vestn Rentgenol Radiol 1:16–21

28.

Romano C, Sellitto A, Chiurazzi F et al (2015) Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. Int J Hematol 101(1):67–74

29.

Baseggio L, Traverse-Glehen A, Petinataud F et al (2010) CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 95(4):604–612

30.

Savilo E, Campo E, Mollejo M et al (1998) Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol 11(7):601–606

31.

Matutes E (2007) Splenic marginal zone lymphoma with and without villous lymphocytes. Curr Treat Options in Oncol 8(2):109–116CrossRef

32.

Gutierrez-Civicos R, Hurtado AM, Torres-Moreno D et al (2017) Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. Pharmacogenet Genomics 27(2):70–77

33.

Bennett M, Schechter GP (2010) Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 47(2):143–147CrossRefPubMed

34.

Tsimberidou AM, Catovsky D, Schlette E et al (2006) Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125–135

35.

Perrone S, D’Elia GM, Annechini G et al (2016) Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leuk Res 44:53–60

36.

Lenglet J, Traullé C, Mounier N et al (2014) Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 55(8):1854–1860

37.

Thieblemont C, Felman P, Berger F et al (2002) Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 3(1):41–47

38.

Xing KH, Kahlon A, Skinnider BF et al (2015) Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol 169(4):520–527

39.

Davidson RN, Wall RA (2001) Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 7(12):657–660CrossRefPubMed

40.

Schreiber DP, Jacobs C, Rosenberg SA et al (1985) The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin’s lymphomas. Int J Radiat Oncol Biol Phys 11(1):31–36

Titel: Surgical management of splenic marginal zone lymphoma
verfasst von: N. D. Kennedy
G. N. Lê
M. E. Kelly
T. Harding
K. Fadalla
D. C. Winter
Publikationsdatum: 17.10.2017
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 2/2018
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-017-1689-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Surgical management of splenic marginal zone lymphoma

Abstract

Objectives

Method

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Objectives

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Thrombolysis for stroke in Ireland: increasing access and maintaining safety in a challenging environment

Comparison of abdominal, vaginal, and laparoscopic hysterectomies in a tertiary care hospital in Turkey

Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy

Burnout and stress amongst interns in Irish hospitals: contributing factors and potential solutions

Pituitary plasmacytoma—a rare presentation of multiple myeloma

Upper limb lymphedema in breast cancer patients in the era of Z0011, sentinel lymph node biopsy and breast conservation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin